Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis | Small Molecules

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis

Related Keywords

Netherlands ,Denmark ,Copenhagen ,Køavn ,Morten Graugaard ,Lundbeckfonden Biocapital ,Novo Nordisk ,Thomas Holm Pedersen ,Novo Group ,Drug Administration ,I Novo Holdings ,International Clinical Trials Registry ,Centre For Human Drug Research ,Novo Seeds Portfolio Company ,Novo Nordisk Foundation ,Roche Venture Fund ,Novo Holdings ,Aarhus University ,Reports Positive Top Line Phase ,Myasthenia Gravis ,Denmarki October ,Board Director ,Holm Pedersen ,Chief Executive Officer ,Quantitative Myasthenia Gravis Score ,Human Drug Research ,Small Molecule ,New Chemical Entity ,Ice ,Chemistry ,Mural ,Inhaled ,Drug Delivery ,Depot ,Flow Release ,